Path Assist is a full-stack Pathology AI platform, equipped with a range of tools that assist in improving the efficiency of the pathology workflow as well as improve the accuracy of reporting. These AI based tools help in automated slide analysis and diagnosis on histopathology images of H&E and IHC stains. Our proprietary machine learning and deep learning based algorithms help in general and organ specific reporting tasks such as tumor identification, classification, scoring and subtyping. Additionally, our algorithms also aid in advanced analytics such as tumor microenvironment (TME) analysis, risk stratification and survival prediction.

Rad Assist enables the radiology reporting workflow through ML-based tools for tumor detection, risk scoring and analysis. These include detections of malignant nodules of the Lung and as well as various lesions on mammograms. Intra-treatment Tumor assessment is a critical step to evaluate the effect of cancer treatment being administered and understand the need to either continue with the same or make changes to the protocol. The tumor tracking tool for treatment decision support tries to augment RECIST scoring for accurate estimate of tumor response on CT. Combined with cross-modality analysis, this becomes a key tool available to Oncologists and tumor boards.

Models can predict with reasonable accuracy in key challenge areas; how well a particular patient will adhere to a treatment plan; how the patient will respond to different modifications in the treatment plan; segment the population into different groups based on their behaviour, and target the highest risk patient groups to improve their outcomes. ML models can go steps further into segmentation or clustering patients into risk-based sub-groups based on response patterns and the evolution of their clinical complexity. Our teams work on advanced tools which can be used by Tumor Boards to discuss available courses of treatment options, consider their potential efficacy projected at a cohort and patient level.

Cancer Pathology involves the study of tissues and has a key role in the diagnosis and prognosis of cancer disease involving behaviour of the disease as well as progress. Quantitative evaluation of certain histopathological biomarkers is requested by the Oncologist in order to be able to decide on the appropriate cancer therapy. The example shown here shows our work with Multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF), a technique that provides high‐throughput multiplex staining and standardized quantitative analysis of tissue studies. These multiplexed tissue imaging technologies enable comprehensive studies of cell composition, functional state and cell‐cell interactions, playing a crucial role in cancer immunotherapy for both research and clinical purposes.

About Us




Onward Assist helps improve cancer treatment outcomes by solving the problem of accurate and timely cancer diagnosis and simplifying the process. Onward enables cancer pathologists and radiologists with automated analytics tools for faster and better reporting, leading to better outcomes. Onward’s AI tools are built in collaboration with leading cancer institutes in India and the US. The Onward team brings extensive experience from the healthcare industry in medical imaging, machine learning and data science. While working on their previous startup, the founders had the opportunity to learn from a significant number of Oncologists, and were inspired by the challenges stemming out of the suboptimal cancer treatment outcomes in general, as well as lack of advanced analysis tools to accurately quantify and report on cancer biomarker tests.

About Us




Onward Assist helps improve cancer treatment outcomes by solving the problem of accurate and timely cancer diagnosis and simplifying the process. Onward enables cancer pathologists and radiologists with automated analytics tools for faster and better reporting, leading to better outcomes. Onward’s AI tools are built in collaboration with leading cancer institutes in India and the US. The Onward team brings extensive experience from the healthcare industry in medical imaging, machine learning and data science. While working on their previous startup, the founders had the opportunity to learn from a significant number of Oncologists, and were inspired by the challenges stemming out of the suboptimal cancer treatment outcomes in general, as well as lack of advanced analysis tools to accurately quantify and report on cancer biomarker tests.

Recognitions


Recognitions





Winner, Healthcare & Lifesciences, Amazon AI Conclave
January 2021


GE Edison(X) Startups
December 2020


Winner, Nasscom Emerge 50 2020
November 2020


Top 50 AI startups, India AI Landscape report
May 2020


Winner, Microsoft EmergeX
February 2020


LIF Fellow, Royal Academy of Engineering London
January 2020


Winner, Startup Award – NHA-Ayushman Bharat
October 2019


Yale Sustainable Health Initiative
June 2019


Top 6 Startups – AEA Conference 2018, Japan
November 2018


Winner, RICH Cancer Innovation Challenge
August 2018


Winner, Lets Ignite 2018
July 2018


Winner, Best Technology Innovation (HYSEA 2018)
July 2018

Coverage of Our Work





01

Meet the six winning startups of the ML Elevate programme...


Go to Article

02

Hyderabad an incubator for firms engaged in war on cancer


Go to Article

03

When software is your radiologist.


Go to Article

04

Unlocking the potential: Artificial Intelligence-based healthcare solutions on the rise


Go to Article

05

These ML-powered startups are the top 30 shortlisted in the ML Elevate program.


Go to Article

06

The top 30 startups in the ML Elevate program


Go to Article

07

Meet the six startups in second cohort of GE Healthcare India accelerator


Go to Article

08

GE Healthcare’s Edison Accelerator announces launch of second Cohort


Go to Article

09

Nasscom announces winners of Emerge 50 2020


Go to Article

10

CB Insights - Onward Assist


Go to Article

11

Nasscom to mentor, fund 17 new deep-tech startups


Go to Article

12

Is DeepTech Disrupting The Old Normal?


Go to Article

13

Onward Assist – Tackling Cancer Through Technology


Go to Article

14

Microsoft’s ‘Highway to a Hundred Unicorns’ selects 54 startups from Tier 2 cities


Go to Article

15

Telangana handholding startups, says Jayesh


Go to Article

16

Yale-India business accelerator to promote innovative health solutions


Go to Article

17

9 startups working to make cancer diagnosis and care easy and convenient


Go to Article

18

How Onward Health helps labs process cancer diagnostic tests faster and better


Go to Article

19

12 Hyderabad startups that are powering the future of healthcare in India


Go to Article

20

RICH shortlists Onward Assist under cancer innovation challenge


Go to Article

21

An Indian startup takes cancer by the horns..


Go to Article

Enablers